We’re honored to announce that we have been selected to participate in the Global Health 2024 initiative! 🌍 Hosted by Reuters, this World Health Day initiative includes a collection of short documentary films featuring leading healthcare innovators. In our film segment, Fabian Gerlinghaus, CEO and Co-Founder of Cellares; Prof. Carl June, cell therapy pioneer, and Bob Levis, CAR-T patient, discuss the history, challenges, and future of CAR-T therapies, and how Cellares’ IDMO Smart Factories, powered by our Cell Shuttles and Cell Qs, can accelerate access to life-saving cell therapies. Watch the full video here 👉 https://lnkd.in/gyxQ5BMZ #WorldHealthDay #GlobalHealth2024 #CellTherapy #Innovation
Cellares
Pharmaceutical Manufacturing
South San Francisco, California 18,603 followers
Accelerating Access to Life-Saving Cell Therapies
About us
Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is both developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. The company’s Cell Shuttle integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers true walk-away, end-to-end automation. Cell Shuttles will be deployed in Cellares’ Smart Factories around the world to meet total patient demand for cell therapies at global scale. Partnering with Cellares enables academics, biotechs, and pharma companies to accelerate drug development and scale out manufacturing, lower process failure rates, lower manufacturing costs, and meet global patient demand. The company is headquartered in South San Francisco, California with its commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. The company is backed by world-class investors and has raised over $355 million in financing.
- Website
-
http://www.cellares.com/
External link for Cellares
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- South San Francisco, California
- Type
- Privately Held
- Founded
- 2019
- Specialties
- biotech, biotechnology, cell therapy, manufacturing, software, medicine , patient care, science, research and development, healthcare, patients, and pharma
Locations
-
Primary
345 Allerton Ave
South San Francisco, California 94080, US
Employees at Cellares
Updates
-
Big strides in personalized cell therapy! Major pharmaceutical companies are implementing new methods to increase the availability of CAR-T therapies for patients by: ☑ Shortening manufacturing time (Novartis) ☑ Using healthier starting cells (Gilead) ☑ Automating manufacturing with Cellares (Bristol Myers Squibb) “Lynelle Hoch, who leads Bristol Myers Squibb's cell therapy business, said its current focus is on increasing manufacturing capacity. Still, it (BMS) said its time to produce the treatments is trending lower and will be helped by its collaboration with Cellares, a development and manufacturing organization with a fully automated cell therapy production platform.” With the industry's focus on increasing manufacturing capacity and decreasing turnaround times, the future of CAR-T therapies looks promising. Read more about these advancements in the latest Reuters article: https://lnkd.in/ep98CtNF #CellTherapyManufacturing #CellTherapy #Reuters
-
-
Financial Times recently published an article discussing the dramatic clinical responses CAR-T therapies are producing in patients with autoimmune diseases. However, manufacturing capacity to treat these large patient populations is an impending challenge: “Only 35,000 lymphoma and leukaemia patients have been treated with CAR-T in the US since its approval seven years ago. In comparison, an estimated 204,000 Americans have systemic lupus erythematosus” Cellares’ integrated and automated manufacturing technology offered through our IDMO can overcome current cell therapy production constraints to meet the total treatment demand of autoimmune patients. Read the full article here: https://lnkd.in/gxs7ssg4
-
-
We are pleased to announce that Kite Pharma will evaluate our automated cell therapy manufacturing platform, the Cell Shuttle. This collaboration with Kite Pharma, a Gilead Sciences Company, is a significant step in our mission to revolutionize cell therapy manufacturing. Together, we are pushing to bring the promise of cell therapies to more patients, faster. Read the full press release: https://lnkd.in/gF-MPFjX #CellTherapyManufacturing #IDMO #CellTherapy
-
-
In the Newsweek article, "The Many Faces of Oncology”, our Co-Founder & CEO, Fabian Gerlinghaus, highlights a significant issue: 'About 20 percent of patients are dying on the waitlist even though they are eligible for approved cell therapies because the industry is unable to meet patient demand.' This is a medical emergency. Learn more about how Cellares' Cell Shuttle platform integrates and automates the entire cell therapy manufacturing process, reducing labor and space requirements by 90% and processing 16 cell therapies simultaneously. This industry 4.0 approach aims to meet global patient demand for these life-saving cell therapies. Read now: https://lnkd.in/gsYX84RB For more Cellares coverage, check out the 🔗 link in the comments!
-
-
In a recent interview with Newsweek, our Co-Founder and CEO, Fabian Gerlinghaus shared his inspiring vision for the future of cell therapy manufacturing and how Cellares is leading the charge, transforming the industry, and enabling groundbreaking therapies to reach their full potential. Read the interview here: https://lnkd.in/graqe5uX #CellTherapyManufacturing #Biotech #IDMO
-
-
🎉 That’s a wrap for ISCT 2024! 🎉 We had a fantastic time at this year’s ISCT conference! Grateful for the opportunity to exchange ideas, showcase our latest work, and build new relationships. A big thank you to the organizers and attendees for an inspiring event. #ISCT24 #CellTherapyManufacturing
-
Nasdaq: Live From MarketSite! Kristina Ayanian recently interviewed our Co-Founder and CEO, Fabian Gerlinghaus on Nasdaq, Live From MarketSite where he discussed Cellares' $380M worldwide capacity reservation and supply agreement with Bristol Myers Squibb and the difference between an IDMO and a conventional CDMO. Watch more: https://lnkd.in/dhnqmhaF #NASDAQ #IDMO #CellTherapyManufacturing #LiveFromMarketSite
-
Cellares has been recognized as one of Fast Company’s Most Innovative Companies for 2024! We're committed to bring the promise of cell therapies to more patients, faster. Access to cell therapies can be life-saving for patients with serious ailments, but scaling these treatments has been a major challenge. At Cellares, we've created an ecosystem of integrated technologies for automated and high-throughput cell therapy manufacturing and quality control. The Cell Shuttle™ and Cell Q™ allow us to produce 10 times more cell therapies compared to conventional processes. Read the full article here: https://lnkd.in/gTB-Pjhq #CellTherapyManufacturing #FastCompany #celltherapy
-
Cellares reposted this
Fabian Gerlinghaus, Co-Founder and CEO of Cellares, joins Nasdaq to celebrate their $380M collaboration with Bristol Myers Squibb for the manufacture of CAR T cell therapies. 👏 Watch more: https://lnkd.in/evVPP6zF